In this work we prepared and characterized two liposomal formulations of a semisynthetic nitric oxide (NO)-releasing doxorubicin (Dox), called nitrooxy-Dox (NitDox), which we previously demonstrated to be cytotoxic in Dox-resistant human colon cancer cells. Liposomes with 38.2% (Lip A) and 19.1% (Lip B) cholesterol were synthesized: both formulations had similar size and zeta potential values and caused the same intracellular distribution of free NitDox, but Lip B accumulated and released NitDox more efficiently. In Dox-resistant human colon cancer cells, Lip A and Lip B exhibited a more favorable kinetics of drug uptake and NO release, and a stronger cytotoxicity than Dox and free NitDox. While Caelyx, one of the liposomal Dox formulations approved for breast and ovary tumors treatment, was ineffective in Dox-resistant breast/ovary cancer cells, Lip B, and to a lesser extent Lip A, still exerted a significant cytotoxicity in these cells. This event was accompanied in parallel by a higher release of NO, which caused nitration of P-glycoprotein (Pgp) and multidrug resistance related protein 1 (MRP1), two transporters involved in Dox efflux, and impaired their pump activity. By doing so, the efflux kinetics of Dox after treatment with Lip B was markedly slowed down and the intracellular accumulation of Dox was increased in breast and ovary drug-resistant cells. We propose these liposomal formulations of NitDox as new tools with a specific indication for tumors overexpressing Pgp and MRP1.

Liposomal Nitrooxy-Doxorubicin: One Step over Caelyx in Drug-Resistant Human Cancer Cells

PEDRINI, ISABELLA;GAZZANO, Elena;CHEGAEV, Konstantin;ROLANDO, Barbara;MARENGO, ALESSANDRO;KOPECKA, JOANNA;FRUTTERO, Roberta;GHIGO, Dario Antonio;ARPICCO, Silvia Maria;RIGANTI, Chiara
2014

Abstract

In this work we prepared and characterized two liposomal formulations of a semisynthetic nitric oxide (NO)-releasing doxorubicin (Dox), called nitrooxy-Dox (NitDox), which we previously demonstrated to be cytotoxic in Dox-resistant human colon cancer cells. Liposomes with 38.2% (Lip A) and 19.1% (Lip B) cholesterol were synthesized: both formulations had similar size and zeta potential values and caused the same intracellular distribution of free NitDox, but Lip B accumulated and released NitDox more efficiently. In Dox-resistant human colon cancer cells, Lip A and Lip B exhibited a more favorable kinetics of drug uptake and NO release, and a stronger cytotoxicity than Dox and free NitDox. While Caelyx, one of the liposomal Dox formulations approved for breast and ovary tumors treatment, was ineffective in Dox-resistant breast/ovary cancer cells, Lip B, and to a lesser extent Lip A, still exerted a significant cytotoxicity in these cells. This event was accompanied in parallel by a higher release of NO, which caused nitration of P-glycoprotein (Pgp) and multidrug resistance related protein 1 (MRP1), two transporters involved in Dox efflux, and impaired their pump activity. By doing so, the efflux kinetics of Dox after treatment with Lip B was markedly slowed down and the intracellular accumulation of Dox was increased in breast and ovary drug-resistant cells. We propose these liposomal formulations of NitDox as new tools with a specific indication for tumors overexpressing Pgp and MRP1.
MOLECULAR PHARMACEUTICS
11
3068
3079
http://pubs.acs.org
doxorubicin; nitric oxide; liposomes; P-glycoprotein
Isabella Pedrini;Elena Gazzano;Konstantin Chegaev;Barbara Rolando;Alessandro Marengo;Joanna Kopecka;Roberta Fruttero;Dario Ghigo;Silvia Arpicco;Chiara Riganti
File in questo prodotto:
File Dimensione Formato  
Mol_Pharm_2014.pdf

non disponibili

Descrizione: PDF editoriale
Tipo di file: PDF EDITORIALE
Dimensione 3.77 MB
Formato Adobe PDF
3.77 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Preprint_pedrini.pdf

embargo fino al 24/07/2015

Descrizione: Versione finale dell'autore
Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 3.7 MB
Formato Adobe PDF
3.7 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2318/148171
Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 24
  • ???jsp.display-item.citation.isi??? 23
social impact